KPIs & Operating Metrics(New)

Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Daily Values

Growth Metrics

Bionano Genomics (BNGO) Capital Expenditures (2017 - 2024)

Bionano Genomics (BNGO) has disclosed Capital Expenditures for 7 consecutive years, with $77000.0 as the latest value for Q2 2024.

Quarterly Capital Expenditures rose 161.11% to $77000.0 in Q2 2024 from the year-ago period, while the trailing twelve-month figure was $77000.0 through Mar 2025, down 94.82% year-over-year, with the annual reading at $103000.0 for FY2024, 93.91% down from the prior year.
Capital Expenditures hit $77000.0 in Q2 2024 for Bionano Genomics, up from $26000.0 in the prior quarter.
In the past five years, Capital Expenditures ranged from a high of $1.6 million in Q4 2022 to a low of -$223000.0 in Q3 2022.
Historically, Capital Expenditures has averaged $440000.0 across 4 years, with a median of $248000.0 in 2022.
Biggest YoY gain for Capital Expenditures was 247.98% in 2023; the steepest drop was 150.81% in 2023.
Year by year, Capital Expenditures stood at $638000.0 in 2021, then soared by 143.1% to $1.6 million in 2022, then dropped by 18.96% to $1.3 million in 2023, then tumbled by 93.87% to $77000.0 in 2024.
Business Quant data shows Capital Expenditures for BNGO at $77000.0 in Q2 2024, $26000.0 in Q1 2024, and $1.3 million in Q4 2023.